🎉 M&A multiples are live!
Check it out!

Reviva Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Reviva Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Reviva Pharmaceuticals Overview

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease, and Parkinson’s disease psychosis and its other drug candidate is RP1208.


Founded

2018

HQ

United States of America
Employees

14

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$23.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Reviva Pharmaceuticals Financials

Reviva Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Reviva Pharmaceuticals achieved revenue of n/a and an EBITDA of -$29.9M.

Reviva Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Reviva Pharmaceuticals valuation multiples based on analyst estimates

Reviva Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$39.5M -$29.9M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$24.3M -$39.3M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Reviva Pharmaceuticals Stock Performance

As of April 15, 2025, Reviva Pharmaceuticals's stock price is $1.

Reviva Pharmaceuticals has current market cap of $36.3M, and EV of $23.3M.

See Reviva Pharmaceuticals trading valuation data

Reviva Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$23.3M $36.3M XXX XXX XXX XXX $-0.85

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Reviva Pharmaceuticals Valuation Multiples

As of April 15, 2025, Reviva Pharmaceuticals has market cap of $36.3M and EV of $23.3M.

Reviva Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Reviva Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Reviva Pharmaceuticals and 10K+ public comps

Reviva Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $23.3M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.8x XXX XXX XXX
P/E -1.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Reviva Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Reviva Pharmaceuticals Valuation Multiples

Reviva Pharmaceuticals's NTM/LTM revenue growth is n/a

Reviva Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.2M for the same period.

Over next 12 months, Reviva Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Reviva Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Reviva Pharmaceuticals and other 10K+ public comps

Reviva Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -24% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Reviva Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Reviva Pharmaceuticals M&A and Investment Activity

Reviva Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Reviva Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Reviva Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Reviva Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Reviva Pharmaceuticals

When was Reviva Pharmaceuticals founded? Reviva Pharmaceuticals was founded in 2018.
Where is Reviva Pharmaceuticals headquartered? Reviva Pharmaceuticals is headquartered in United States of America.
How many employees does Reviva Pharmaceuticals have? As of today, Reviva Pharmaceuticals has 14 employees.
Who is the CEO of Reviva Pharmaceuticals? Reviva Pharmaceuticals's CEO is Dr. Laxminarayan Bhat, PhD.
Is Reviva Pharmaceuticals publicy listed? Yes, Reviva Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Reviva Pharmaceuticals? Reviva Pharmaceuticals trades under RVPH ticker.
When did Reviva Pharmaceuticals go public? Reviva Pharmaceuticals went public in 2020.
Who are competitors of Reviva Pharmaceuticals? Similar companies to Reviva Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Reviva Pharmaceuticals? Reviva Pharmaceuticals's current market cap is $36.3M
Is Reviva Pharmaceuticals profitable? Yes, Reviva Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.